26 August 2020
AstraZeneca has started dosing participants in a Phase I clinical trial of monoclonal antibody (mAb) combination therapeutic AZD7442 to prevent and treat Covid-19. AZD7442, which combines two mAbs obtained from Covid-19 convalescent patients, was discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June this year. The Phase I study will enrol up to 48 participants aged 18 to 55 in the UK.
Translate Bio has reported that its Covid-19 vaccine candidate, which is being developed in collaboration with Sanofi, elicited an immune response in early-stage animal studies. In a regulatory filing, Translate Bio cited Sanofi's presentation slides, which revealed that three doses of the vaccine candidate triggered neutralising antibodies and T-cell responses in the preclinical tests. The company added that the potential vaccine will be further tested in an early- to mid-stage human trial that is scheduled to commence in November, according to Reuters.
Indonesia’s PT Bio Farma has entered into two agreements for the supply, local manufacturing and technology licensing of China-based Sinovac Biotech’s Covid-19 vaccine candidate, CoronaVac. Sinovac has committed to provide bulk vaccine to PT Bio Farma so it can produce at least 40 million doses of the vaccine in Indonesia before March 2021. After March, the Chinese company will continue to supply the required quantity until the end of 2021.
The University of Cambridge has received £1.9m grant from the UK Government to conduct clinical trials of its potential Covid-19 vaccine in the second half of this year or early next year. The funding will support an alliance between the university, a Cambridge spin-out company DIOSynVax and the University Hospital Southampton NHS Foundation Trust. The clinical trial of the vaccine candidate is set to occur at the National Institute for Health Research (NIHR).